Literature DB >> 7618490

Changes in dopamine D2 and GluR-1 glutamate receptor mRNAs in the rat brain after treatment with phencyclidine.

H Tomita1, M Hikiji, Y Fujiwara, K Akiyama, S Otsuki.   

Abstract

In situ hybridization of slide-mounted brain sections from rats subjected to acute and chronic phencyclidine treatment was carried out using synthetic oligonucleotides complementary to dopamine D2-receptor and non-N-methyl-D-aspartate (NMDA) glutamate-receptor-subunit (GluR-1) mRNAs. There was no significant difference in either the D2-receptor or the GluR-1 mRNA levels in any brain region of the acute phencyclidine (10 mg/kg)-treated and control groups. However, chronic administration of phencyclidine (10 mg/kg/day, 14 days) significantly decreased the dopamine D2-receptor mRNA level in the caudate-putamen (by 27%, P < 0.01) and significantly increased the GluR-1 mRNA level in the prefrontal cortex (by 29%, P < 0.001). These results suggest that the chronic pharmaco-behavioral effects of phencyclidine may involve expression of both dopamine- and non-NMDA glutamate-receptor mRNAs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618490     DOI: 10.18926/AMO/30393

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  2 in total

1.  Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors.

Authors:  Claude Sebban; Brigitte Tesolin-Decros; Jorge Ciprian-Ollivier; Laurent Perret; Michael Spedding
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Similarities in the behavior and molecular deficits in the frontal cortex between the neurotensin receptor subtype 1 knockout mice and chronic phencyclidine-treated mice: relevance to schizophrenia.

Authors:  Zhimin Li; Mona Boules; Katrina Williams; Andres Gordillo; Shuhua Li; Elliott Richelson
Journal:  Neurobiol Dis       Date:  2010-07-24       Impact factor: 5.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.